Eric Topol, MD
Cardiovascular Disease · la Jolla, CANPI 1487723714
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (36.6%), ownership interests and speaking fees — rather than concentrated in one kind of arrangement. Dexcom, Inc. accounts for 95.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $492,714 and has fallen 89.6% since, to $51,335 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 42 payments — averaging $53,019 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$2.1M
- Carlsmed, Inc.$51K
- Illumina, Inc.$48K
- Genentech USA, Inc.$6K
- Cue Health Inc.$867
- Boston Scientific$400
- plus $238 from 2 others
Across 8 payments — averaging $2623.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$21K
What the payments were for
- Consulting fees$815,39137%
- Speaking & faculty fees$433,39319%
- Grants$317,37114%
- Travel & lodging$3,2820%
- Food & beverage$3,9320%
- Gifts$1,4480%
- Entertainment$130%
- Ownership interest$651,95429%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 22 | $2,120,710 |
| Carlsmed, Inc. | 3 | $50,896 |
| Illumina, Inc. | 9 | $48,075 |
| Genentech USA, Inc. | 3 | $5,598 |
| Cue Health Inc. | 1 | $867 |
| Boston Scientific | 1 | $400 |
| Asahi Intecc USA, Inc. | 2 | $213 |
| Acist Medical Systems, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$631,752
- DEXCOM G6 CGM SYSTEM$338,055
- DEXCOM CGM$337,353
- aprevo$50,896
- NovaSeq 6000Dx Sequencer Instrument$25,015
- Infectious Disease$22,990
- Cue Health Monitoring System$867
- GENERAL - THERAPIES$400
- PERIPHERAL VASCULAR$168
How this compares
$2,226,784 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in la Jolla
- Pam Taubla Jolla$1.2M
- Douglas Gibsonla Jolla$727K
- Douglas Triffonla Jolla$176K
- Judith Swainla Jolla$151K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.